Introduction

Please take a moment and listen to the introductory video on your left. Then, view the video below and follow the instructions for the quiz.

The video below from the Psychedelic Science in the 21st Century is available for continuing education credit through the co-sponsorhip of the Mulitdisciplinary Association for Psychedelic Studies and the Spiritual Competency Resource Center for many physicians, psychologists, social workers, MFTs, nurses and other healthcare professionals.



INSTRUCTIONS

    1. Watch the video on your left. There is no charge for viewing the video
    2. Answer the questions below.
    3. When finished, press the Score My Quiz button. After that you will have an option to checkout and print your CE/CME certificate.*
    4. To view CE/CME information click here

Christopher Wiegand, M.D Results from a Study of Psilocybin to Treat Obsessive-Compulsive Disorder in Human


Course Presenter(s):
Author(s): Christopher Wiegand, M.D. | (click author name for biography)


Course Description: This study investigated the safety, tolerability, and clinical effects of psilocybin, a potent serotonin agonist, in nine patients with Obsessive Compulsive Disorder (OCD). Subjects participated in up to 4 single-dose exposures to psilocybin, separated by at least 1 week, in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Sessions lasted 8-hours in a controlled clinical environment, followed by overnight hospitalization. The Yale-Brown Obsessive Compulsive Scale (YBOCS) was administered at specific intervals, and vital signs monitored. Marked decreases in OCD symptoms were observed in all subjects during 1 or more of the testing sessions (23%- 100% decrease in YBOCS score) and generally lasted at least 24 hours. In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Christopher Wiegand, M.D., is a psychiatrist currently in private practice in Tucson, Arizona. His clinical practice includes outpatient psychopharmacology and psychotherapy, hospital and nursing home consultation, and electroconvulsive therapy. In addition, Dr. Wiegand is a Clinical Assistant Professor in the Department of Psychiatry at the University of Arizona; he participates in research, resident supervision, and medical student education. He received his B.A. in Archaeology at the University of Virginia in 1995, his M.D. at the University of Virginia in 1999, and completed Psychiatry residency training at the University of Arizona in June, 2003. Dr Wiegand will be discussing the safety, tolerability, and efficacy of psilocybin in patients with Obsessive-Compulsive Disorder (OCD).
Date of original release: April 18, 2010 Termination date (date after which enduring material is no longer certified for credit): April 17, 2012

Chris Wiegand, M.D.,-Results from a study of psilocybin to treat obsessive-compulsive disorder in human subjects from MAPS: Psychedelic Science on Vimeo.

True/False Comprehension Quiz

QuestionAnswer
Current OCD treatment with SSRIs (selective serotonin reuptake inhibitors) is only effective in 40 to 60% of OCD patients.
The results equivalent changes in OCD traits following sessions in which participants were given placebos instead of psilocybin.
The results Wiegand presents show significant adverse effects/events documented after 29 sessions with psilocybin.
Psilocybin is a potent activator at the serotonin 1A, 2A and 2C receptors involved in OCD.

Rate this Course:
Rating of this course out of 1 votes:0%

 
 


Spiritual Competency Resource Center Website